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Abstract
Structural and functional studies assessed the membrane actions of the N terminus of HIV-1 glycoprotein 41 000 (gp41).
Earlier site-directed mutagenesis has shown that key amino acid changes in this gp41 domain inhibit viral infection and
syncytia formation. Here, a synthetic peptide corresponding to the N terminus of gp41 (FP; 23 residues, 519^541), and also
FP analogs (FP520V/E with ValCGlu at residue 520; FP527L/R with LeuCArg at 527; FP529F/Y with PheCTyr at 529;
and FPCLP1 with FP truncated at 525) incorporating these modifications were prepared. When added to human
erythrocytes at physiologic pH, the lytic and aggregating activities of the FP analogs were much reduced over those with the
wild-type FP. With resealed human erythrocyte ghosts, the lipid-mixing activities of the FP analogs were also substantially
depressed over that with the wild-type FP. Combined with results from earlier studies, theoretical calculations using
hydrophobic moment plot analysis and physical experiments using circular dichroism and Fourier transform infrared
spectroscopy indicate that the diminished lysis and fusion noted for FP analogs may be due to altered peptide-membrane
lipid interactions. These data confirm that the N-terminal gp41 domain plays critical roles in the cytolysis and fusion
underlying HIV-cell infection. ß 1999 Elsevier Science B.V. All rights reserved.
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Fourier transform infrared
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Abbreviations: CD, circular dichroism; C/P, cholesterol/phospholipid molar ratio; DMSO, dimethyl sulfoxide; 2D-NMR, two-dimen-
sional nuclear magnetic resonance; ESR, electron spin resonance; FP, HIV amino-terminal peptide 519^541 of gp41 (HIV-1 LAV1a
strain); FP527L/R, a FP analog in which Leu-527 is replaced by Arg; FP520V/E, a FP analog in which Val-520 is replaced by Glu;
FP529F/Y, a FP analog in which Phe-529 is replaced by Tyr; FPCLP1, a truncated FP peptide 526^541; FPCLP2, a truncated FP peptide
525^541; FTIR, Fourier transform infrared; gp41, glycoprotein 41 000 of HIV-1; gp120, glycoprotein 120 000 of HIV-1; HA2, in£uenza
virus hemagglutinin protein; HFIP, hexa£uoroisopropanol; HIV-1, human immunode¢ciency virus, type-1; HIValaÿE2, a N-terminal gp41
peptide analog in which Val-520 is replaced by Glu (HIV-1 HXB-2 strain; 23 residues 519^541); LUV, large unilamellar vesicles ; PBS,
phosphate bu¡ered saline; P/L, peptide to lipid molar ratio; POPC, 1-palmitoyl-2-oleoylphosphatidylcholine; POPG, 1-palmitoyl-2-
oleoylphosphatidylglycerol ; R18, octadecyl rhodamine B chloride; RBC, red blood cell ; SDS, sodium dodecyl sulfate; SP-3, a N-terminal
gp41 analog with 3 amino acids removed (residues 520^522; HIV-1 LAV1a strain); SP-4, a N-terminal gp41 analog with 4 amino acids
removed (residues 520^523; HIV-1 LAV1a strain); SUV, small unilamellar vesicles; TFE, tri£uoroethanol
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1. Introduction
Previous ¢ndings support the hypotheses that the
amino-terminal peptide (FP; 23 amino acid residues
519^541 [1] ; Table 1) of glycoprotein 41 000 (gp41) is
involved in the fusion processes underlying HIV-1
infection of host cells [2]. In myxoviruses and para-
myxoviruses, the fusion site on viral envelope protein
is a conserved hydrophobic amino acid sequence at
the N terminus of the F1 protein [3]. Gallaher [4] and
Gonzalez-Scarano et al. [5] each noted extensive ho-
mologies of these sequences with those of the N ter-
minus of gp41, and suggested that the N-terminal
gp41 peptide is similarly involved in the fusion of
the HIV-1 envelope with target cells. When the
HIV-1 glycoprotein 120 000 (gp120) binds to the lym-
phocyte CD4 receptor, the N-terminal gp41 peptide
is activated, which in turn may attack the host cell
surface [2,6,7]. According to one model, the N termi-
nus of gp41 penetrates deeply into the host cell mem-
brane [8], and the viral envelope gp41 acts as a
bridge, fusing the target cell surface with the HIV-1
lipid bilayer [9,10]. Experimental support for these
hypotheses are site-directed mutagenesis studies
showing defective gp41 fusion activity for various
modi¢cations in the N-terminal HIV-1 gp41 domain,
including substitution of hydrophobic amino acids
with polar residues [11^15], replacement of highly
conserved Gly residues with Val [16] or deletion of
short amino acid sequences [17]. Site-directed muta-
genesis of the in£uenza hemagglutinin protein (HA2)
similarly indicated that several point mutations in the
N-terminal domain either abolished or shifted the
pH response to fusion [18,19]. Besides overall hydro-
phobicity, Delahunty et al. [16] suggested that the
precise sequence and structure of viral fusion pepti-
des were critical for function.
A complementary experimental approach has been
to prepare synthetic peptides based on the known N-
terminal gp41 sequence, and to then determine
whether the biologic activity attributed to the peptide
domain in the virus is also seen with the isolated
peptide. For example, synthetic peptides based on
the N terminus of HIV-1 gp41 induced leakage of
lipid vesicles [20^27]. These studies support the Gal-
laher [4] proposal that the N-terminal domain of
gp41 may be partly responsible for the cytolytic ac-
tions of whole HIV-1 virions. Consistent with this
hypothesis are the ¢ndings that FP lysed both
CD4 (cultured Hut 78 lymphocytes) and CD43 (hu-
man erythrocytes) cells [28]. Addition of N-terminal
gp41 peptides to model liposomes also promoted lip-
id mixing [20,21,23^26,29,30]. With human erythro-
cytes, FP not only triggers rapid lipid mixing be-
tween cell membranes, but also produces multicell
aggregates [31]. These data suggest that much of
the fusogenic actions of HIV-1 gp41 are retained
by the N-terminal peptide.
In view of the likely participation of the N-termi-
nal gp41 region in HIV-1 fusion, it is important to
elucidate the structure of this domain. The preferred
approach would be to determine its three-dimension-
al structure using X-ray crystallography of the gp41
protein. Unfortunately, earlier X-ray analyses have
been performed only on gp41 proteins lacking the
N-terminal region, because full-length gp41 proteins
do not form crystals [32^35]. Instead, circular dichro-
ism (CD) and conventional Fourier transform infra-
red (FTIR) spectroscopy have been used to study the
conformation of N-terminal gp41 peptides. These
techniques indicated that N-terminal gp41 peptides
assume variable proportions of K-helix, L and ran-
dom conformations in structure-promoting solvents
and membrane mimics, depending on solvent polar-
ity, lipid charge, peptide concentration and cation
concentrations [8,20,21,23^27,29,30]. Further ori-
ented FTIR spectroscopy of N-terminal gp41 peptide
indicated an oblique insertion of the K-helical region
into lipid bilayers [23,29]. In addition, methodologies
that are more ‘residue-speci¢c’ than CD and FTIR
spectroscopy have been used to de¢ne the conforma-
tion and topography of N-terminal gp41 peptides in
membrane mimics. With FP spin-labeled at either
Ala-519 or Met-537 incorporated into lipids, electron
spin resonance (ESR) studies indicated that the N-
terminal Ala-519 inserted deeply into the membrane
bilayer, while Met-537 resided at the aqueous-mem-
brane interface [8]. In a more recent 2D nuclear mag-
netic resonance (2D-NMR), circular dichroism and
molecular modeling investigation of FP in either
structure-promoting tri£uoroethanol (TFE) or deter-
gent sodium dodecyl sulfate (SDS), Chang et al. [36]
reported high levels of K-helix. Speci¢cally, FP in
50% TFE assumed an K-helical conformation for
residues Ile-522 to Ala-533, while the corresponding
K-helix spanned residues Val-520 to Gly-534 for FP
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bound to SDS micelles [37]. In further NMR, £uo-
rescence and ESR studies of FP bound to SDS,
Chang et al. [37] observed deep penetration of the
amphipathic K-helical segment (residues Gly-524 to
Gly-534) into the micellar interior. Despite the above
extensive spectroscopic results, there is no generally
accepted structural model for how the N-terminal
gp41 peptide induces membrane lysis and fusion.
A fundamental concern in any structural and func-
tional investigation of synthetic HIV-1 fusion pepti-
des is whether the activity of the isolated peptide
bears any relevance to that of the peptide in the
virus. A critical test of the signi¢cance of viral fusion
peptide activities comes from prior site-directed mu-
tagenesis studies, indicating that modi¢cation of key
residues in the N-terminal gp41 domain reduced HIV
infectivity and syncytia formation [12^15,17]. Here,
we explore the membrane interactions of a structur-
ally diverse library of synthetic FP analogs, incorpo-
rating some of the above modi¢cations which inhibit
gp41 protein fusion. Lytic and fusogenic activities
were studied with human erythrocytes, chosen be-
cause the red cell bilayer lipid composition, asymme-
try and molar cholesterol/phospholipid (C/P) ratio
approximates those in both the HIV-1 envelope
and target cells [9]. We report diminished lytic and
fusion activities with our suite of FP variants, con-
¢rming that the synthetic N-terminal gp41 peptides
may be used as a model for the corresponding N-
terminal domain in the full-length HIV-1 gp41 pro-
tein. Furthermore, theoretical calculations using hy-
drophobic moment plots [38] and physical studies
employing CD and FTIR spectroscopy on FP and
FP variants were performed to map the functionally
active regions of the N-terminal gp41 peptide, and to
de¢ne the structural role of critical amino acid resi-
dues.
2. Materials and methods
2.1. Materials
Octadecyl rhodamine B chloride (R18) was from
Molecular Probes (Eugene, OR). 1-Palmitoyl-2-
oleoylphosphatidylcholine (POPC) and 1-palmitoyl-
2-oleoylphosphatidylglycerol (POPG) were from
Avanti (Alabaster, AL).
The 23-amino acid N-terminal sequence of gp41
(FP; Table 1) of the HIV-1 strain LAV1a was pre-
pared with an ABI 431A peptide synthesizer, and
puri¢ed as described earlier [39]; FP encompasses
amino acid residues 519^541 of HIV-1 gp41 [1].
The following FP variants (Table 1) were similarly
prepared: FP520V/E, FP527L/R (designated
FP526L/R in Mobley et al. [31]), FP529F/Y,
FPCLP1 (residues 526^541), and FPCLP2 (residues
525^541). These FP variants were based on earlier
site-directed, mutagenic experiments that led to de-
fective gp41 fusion activity, with FP520V/E and
FP527L/R representing the gp41.2 and gp41.9 mu-
tants [12,13], FP529F/Y representing the FP522F/Y
mutant [14], and FPCLP1 representing the penv-
7RRE mutant [17]. The expected molecular masses
of FP and FP variants were obtained by fast-atom
bombardment and electrospray mass spectrometry
(UCLA Center for Molecular and Medical Sciences
Mass Spectrometry). Quantitative amino acid com-
positions for the peptides were determined at the
UCLA Protein Microsequencing Facility.
2.2. Preparation of human red blood cells (RBC) and
resealed human RBC ghosts
RBCs were prepared using outdated units from the
local blood bank [28]. All units tested negative for
Table 1
Amino acid sequences of the N-terminal peptide (FP) of HIV-1
gp41 and FP variants
a The numbering sequence of Myers et al. [1] was used for the
HIV-1 strain LAV1a ; amino acids are indicated by one-letter
codes.
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antibodies to HIV-1, and hepatitis B and D. Red
cells were washed three times in 0.85% NaCl, and
packed cells from the last wash were suspended in
isotonic (phosphate-bu¡ered saline (PBS)) bu¡er,
consisting of 120 mM NaCl-2.7 mM KCl-10 mM
Na2HPO4 (pH 7.4). Lysed and resealed RBC ghosts
were prepared according to the method of Sze and
Solomon [40], with several modi¢cations [31].
2.3. Hemolysis assays of human RBCs
For testing of peptide-induced hemolysis, small
aliquots (910 Wl) of concentrated FP, or FP variants
in 50% DMSO were added to 0.5 ml of the isotonic
PBS bu¡er to yield the desired peptide concentration.
Aliquots (10 Wl) of the packed, washed cells were
then added, and after 30 min at 37‡C, the suspension
was centrifuged at approx. 5000Ug for 1.5 min and
the supernatant analyzed spectrophotometrically for
hemoglobin at 540 nm [28]. Percent lysis was calcu-
lated, using a reference of the average of three tubes
in which 10 Wl of packed cells were incubated in 0.5
ml of distilled water for the duration of the experi-
ment.
2.4. Lipid mixing (fusion assay)
Lipid mixing between red cell membranes was
quantitated from the relief of £uorescence self-
quenching of the membrane-incorporated £uorescent
probe, R18. Fusion of R18-labeled red blood cell
ghosts with unlabeled ghosts reduces the membrane
surface density of the £uorophore, thereby producing
an increase in £uorescence intensity [41].
For lipid-mixing experiments, the resealed ghosts
were divided into two equal portions: one aliquot
was stored on ice, while the other was incubated
with R18 for 1 h at room temperature in the dark.
R18 was added with vigorous vortexing to a ¢nal
concentration of 1 mole/50 mole lipid [31]. Unincor-
porated R18 was removed by gel ¢ltration on a
Sephadex G-75 column (incubation bu¡er: 120 mM
KCl/30 mM NaCl/10 mM Na2HPO4/0.1 mM
EDTA), and the unlabeled, resealed ghosts were di-
luted to the same volume as the labeled, resealed
ghosts collected from the column.
Fluorescence intensities were recorded using a Per-
kin-Elmer 650-40 £uorescence spectrophotometer at
37‡C. For fusion measurements, zero £uorescence
(F0) was taken as the emission intensity at 590 nm
(560 nm, excitation wavelength) of the labeled and
unlabeled resealed ghosts (1:1) before the fusion
agent is added, and 100% £uorescence (F100) is the
corresponding intensity after the incubation medium
is made 1% in Triton X-100. Fs represents the £uo-
rescence intensity, measured for a 1:1 mixture of
labeled and unlabeled, resealed ghosts on addition
of the putative fusion agent for the indicated time.
Accordingly, the percent fusion may be de¢ned as
% fusion  100UF s3F0=F1003F0 1
2.5. Coulter counter sizing of human erythrocytes
The aggregation state of human red blood cells
was assessed with Coulter counter sizing [31]. Ali-
quots (10 Wl) of washed, packed red blood cells
were incubated in 0.5 ml PBS with the indicated
agent at 37‡C for 30 min. Agents were added as
described above for hemolysis assays. At the end of
the incubation an aliquot of the mixture was diluted
1/50 000 in isotonic PBS in a 20 ml disposable blood
vial (Baxter Diagnostics, Irvine, CA). Particle num-
bers in each of the 15 size ranges were determined
with a Coulter Counter-Model ZBI (Coulter Elec-
tronics, Hileah, FL), equipped with a stirrer. The
total particle volume (VT) was calculated as the sum-
mation, over each of the 15 channels, of the number
(NC) of particles in each channel multiplied by the
maximum particle volume (VMC) in each channel. %
total volume in each channel (%TVC) is then de¢ned
as:
% total volume  %TVC  100UNCUVMC=VT
2
2.6. CD spectroscopy
CD measurements were made with an AVIV 62DS
spectropolarimeter (AVIV Associates, Lakewood,
NJ), ¢tted with a thermoelectric temperature control-
ler [42]. For experiments with peptides in either an
aqueous or membrane-mimic solvent [43], 10 WM
peptides were respectively suspended in PBS or in
hexa£uoroisopropanol (HFIP):water (7:3, v/v) with
10 mM phosphate, pH 7.4 (i.e., HFIP solution). CD
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spectra were then recorded on peptide dispersions in
0.1^0.5 mm light path demountable cells, scanned
from 250^260 nm to 195 nm at a rate of 10 nm/
min and a sample interval of 0.2 nm [42,44]. The
instrument was routinely calibrated with (+)-10-cam-
phorsulfonic acid (1 mg/ml) and a 1 mm path length
cell [45], and the ellipticity expressed as the mean
residue ellipticity, [a]MRE (deg cm2 dmol31). Peptide
sample concentrations were determined from quanti-
tative amino acid analysis (UCLA Microsequencing
Facility, Los Angeles, CA). The percentage of K-he-
lix conformation in the peptide was estimated using
reference spectra [46].
2.7. FTIR spectroscopy
Infrared spectra were recorded at 25‡C using a
Mattson Research Series FTIR spectrometer with a
DTGS detector, averaged over 64 scans at a resolu-
tion of 2 cm31. For measurements with peptides in a
lipid environment, large unilamellar liposomes
(LUV) of POPC:POPG (1 mole:1 mole) lipids in
PBS (500 nmoles lipid/ml) of approx. 100 nm diam-
eter were prepared freeze thawing ¢ve times, fol-
lowed by ¢vefold extrusion through polycarbonate
¢lters using a LipoFast apparatus (Avestin, Ottawa,
CA) [44]. Peptides were added to the liposome dis-
persion from the HFIP solution, and allowed to in-
cubate with the liposomes for 1 h. FTIR spectra were
measured on the above unchromatographed pepti-
de:liposome mixtures, and also on these peptide:lipid
samples passed through a Sephadex G-50 column to
remove non-liposome associated peptide. Chromato-
graphed and unchromatographed lipid-peptide sam-
ples were dried onto a 50 mmU20 mmU3 mm 45‡
horizontal ATR crystal (Spectral Solutions, Canyon,
CA) by nitrogen gas-enhanced evaporation. The
ATR crystal with the lipid-peptide ¢lm was sand-
wiched in a chamber fabricated from black anodized
aluminum [47], and mounted on the horizontal ATR
¢tted with a Minco heater strip controlled by an
Omega (Stamford, CT) temperature regulator. The
lipid-peptide sample was then hydrated for 2 h by
passing nitrogen-2H2O vapor through ports in the
cell body. Martin et al. [23] earlier noted that the
peptide concentration is proportional to the area
(Samide) of the amide I band (1680^1600 cm31), while
the lipid concentration is proportional to the area
(SXCOlipid) of the lipid X(C = O) band (1770^1700
cm31). Accordingly, the peptide/lipid ratio is propor-
tional to the following ratio: (Samide)/(SXCOlipid).
The relative contributions of the various peptide
conformations in the lipid ¢lm were estimated from
analysis of the amide I bands of the chromato-
graphed sample [42]. The spectrum of the lipid ¢lm
without peptide was subtracted from that of samples
with peptide associated with lipid. The amounts of K-
helix, turn, L-structure, and disordered conforma-
tions were determined by Fourier self-deconvolution
for band narrowing and area calculations of compo-
nent peaks determined with curve ¢tting software
supplied by Mattson and based on procedures de-
scribed by Kauppine et al. [48]. The frequency limits
for the di¡erent structures were as follows: K-helix
(1662^1645 cm31), L-sheet (1637^1613 cm31 and
1689^1682 cm31), L-turns (1682^1662 cm31) and dis-
ordered or random (1645^1637 cm31) [42].
2.8. Hydrophobic moment analysis
The association of peptide domains with mem-
branes was predicted with hydrophobic moment
analysis [38]. The average hydrophobicity (abscissa)
is plotted vs. hydrophobic moment (ordinate) for
segments assuming either K-helix or L-sheet confor-
mations. The peptide location is then predicted by
noting whether the sequence coordinates lie in the
membrane surface, transmembrane or globular re-
gions in these hydrophobic moment plots [8,44].
2.9. Molecular modeling
Segments of the N-terminal peptide of HIV-1 (FP)
were modeled with Insight II software, version 97.0
(Molecular Simulations, San Diego, CA) running on
a Silicon Graphics R10000 Indigo-2 High Impact
workstation (Beckman Research Institute of the
City of Hope core facility).
3. Results
3.1. Hemolytic actions of FP and FP variants
The lytic actions of the N-terminal peptide of
HIV-1 gp41 (FP) and FP variants were examined
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with human red blood cells suspended in an isotonic
bu¡er at 37‡C for 30 min. Fig. 1 shows that FP
induces a dose-dependent hemolysis, with 40% lysis
occurring at 20 WM. If it is assumed that the red cell
membrane uptake of FP is quantitative, incubation
of 20 WM FP with RBCs will yield a peptide/lipid
ratio of approx. 1/7.5 (Fig. 1). Maximal hemolysis
of 100% was produced at a higher FP concentration
of 100 WM. Previous batches of synthetic FP induced
similar lytic results with human red cells [28,31,49].
Control experiments indicate that the highest concen-
trations of carrier DMSO (i.e., 2.6^5%) did not sig-
ni¢cantly promote hemolysis. Fig. 1 also shows that
the FP variants were much less hemolytic than the
wild-type FP for the entire dose range (20^100 WM)
tested. To assess the relative inhibitory e¡ects of the
amino acid substitutions or deletions in the FP var-
iants, maximal hemolysis (100%) was arbitrarily re-
de¢ned as that observed after incubating 40 WM FP
and erythrocytes for 30 min. Table 2 shows that 40
WM concentrations of each FP variant produced
minimal lysis (9 23%) when compared to that of FP.
3.2. Lipid-mixing (fusion) actions of FP and FP
variants
Fluorescence measurements were carried out to
Fig. 1. Dose-dependent e¡ects of the N-terminal peptide of
HIV-1 gp41 (FP; b) and the FP variants FP527L/R (U),
FP520V/E (8), FP529F/Y (R), FPCLP1 (F) and FPCLP2 (7)
on the isotonic hemolysis of human red blood cells. Amino
acid sequences for peptides are shown in Table 1. ‘Zero’ points
for each curve re£ect the hemolysis noted with the carrier con-
centration of DMSO (2.6%). Red cells (1U1011 cells/l) were in-
cubated with peptide for 30 min at 37‡C. % hemolysis is deter-
mined as described in Section 2; 100% hemolysis is de¢ned by
incubating 10 Wl of packed red cells in 0.5 ml of distilled water
for 30 min at 37‡C. Numbers in parentheses next to the FP he-
molysis curve indicate the lipid:FP molar ratio, calculated as-
suming quantitative uptake of peptide. Results are reported as
the mean of duplicate measurements, and are representative of
three independent experiments.
Table 2












FP 100 100 100 100
FP520V/E 6 2f 16 58 51
FP529F/Y 4g 22 4 35
FP527L/R 6 2h 16 8 0
FPCLP1 0i 8 0 0
FPCLP2 ^j 23 0 11
aSee Table 1 for amino acid sequences of FP and FP variants.
b% of wild-type gp41 protein fusion = 100U[(modi¢ed gp41-induced fusion)/(wild-type gp41-induced fusion)].
c% of FP-induced hemolysis = 100U[(% hemolysis with 40 WM peptide)/(% hemolysis with 40 WM FP)] from data in Fig. 1.
d% of FP-induced lipid mixing of red cell ghosts = 100U[(% lipid mixing with 40 WM peptide at 8 min)/(% lipid mixing with 40 WM
FP at 8 min)] from data in Fig. 2.
e% of 40 WM FP-induced aggregation was determined from Eq. 3 and data in Fig. 3.
f gp41 containing ValCGlu at residue 520 [12].
ggp41 containing PheCTyr at residue 529 [14].
hgp41 containing LeuCArg at residue 527 [12].
igp41 lacking residues 519^525 [17].
jNot determined.
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determine the lipid-mixing (fusion) e¡ects of FP on
resealed erythrocyte ghosts. These assays rely on R18
being heavily self-quenched when inserted in a mem-
brane lipid bilayer at high £uorochrome/lipid (ap-
prox. 1/100). In the absence of lipid mixing, the
dye only very slowly transfers from the bilayers of
the labeled resealed ghosts to those of the unlabeled
resealed ghosts. When lipid-mixing fusion occurs, the
dye is rapidly diluted throughout the system and re-
lief of self-quenching results in an increase in £uo-
rescence. In time-course studies at 37‡C, R18-labeled
and unlabeled resealed ghosts were incubated with 40
WM FP, and progressively increasing lipid mixing
was noted (Fig. 2). Essentially maximum lipid mixing
occurred in approx. 7 min. The magnitude and ki-
netics of FP-induced lipid mixing with resealed hu-
man erythrocyte ghosts are comparable to results
reported with earlier batches of FP [31]. Control ex-
periments indicated that the highest concentration of
carrier solvent (2.6% DMSO) did not promote lipid
mixing; the ‘zero’ time lipid mixing was identical
with or without 2.6% DMSO.
Our suite of FP analogs was also investigated for
time-dependent e¡ects on lipid mixing between re-
sealed erythrocyte ghosts. Fig. 2 demonstrates that
40 WM FP520V/E promotes lipid mixing, with a sim-
ilar time-course to that seen with FP; however, the
maximal increase in lipid mixing for FP520V/E is
signi¢cantly less than that observed for FP. With
40 WM concentrations of the FP variants FP527L/
R, FP529F/Y, FPCLP1 or FPCLP2, negligible in-
creases in lipid mixing were noted over the time-
course of the experiments (Fig. 2). To determine
the relative fusogenic activity of the FP and FP var-
iants, maximal lipid mixing (100%) was arbitrarily
rede¢ned as that observed after incubating 40 WM
FP and erythrocytes for 8 min. Table 2 indicates
that the lipid-mixing activity of 40 WM FP520V/E
was only 58% of that of FP, and also con¢rms that
40 WM concentrations of the other FP variants are
non-fusogenic.
3.3. RBC aggregating actions of FP and FP variants
Since the above results showed that the FP var-
iants have reduced cytolytic and fusogenic activities
compared to those of wild-type FP, the peptides were
then tested for aggregation of human red cells.
Coulter counter experiments were conducted on
washed, packed red cells incubated in isotonic PBS
with 40 WM concentrations of FP, FP520V/E,
FP527L/R, FP529F/Y, FPCLP1 or FPCLP2 for 30
min. Counts were made for particles in channels
ranging in maximum particle volume (W3) from 2 to
32 768. Plots of the %(total volume), %TV, versus the
maximum particle volume are shown in Fig. 3, where
%TV is the percent fraction of the red cell particle
volume in a given channel to the total volume of the
particles in all channels (see Section 2). For 40 WM
FP and carrier DMSO (2.6%), the largest %TV oc-
curred with a maximum particle volume of 256 W3
(Fig. 3). Control studies with DMSO (2.6%) alone
indicated much smaller particle sizes for red blood
cells. Speci¢cally, the 64 W3 channel had the largest
%TV for red cells treated with only carrier DMSO,
Fig. 2. Time dependence of lipid mixing (fusion) induced by the
N-terminal peptide of HIV-1 gp41 (FP), and FP variants using
resealed human erythrocyte ghosts at 37‡C. Percent fusion is
measured by the increase in £uorescence of the lipid-soluble
probe, R18, due to relief of self-quenching upon fusion of la-
beled and unlabeled resealed ghosts (see Section 2). Complete
(100%) fusion is taken as the maximal £uorescence resulting
from treatment with 1% Triton X-100. R18-labeled (200 Wl) re-
sealed ghosts and unlabeled (200 Wl) resealed ghosts were incu-
bated with the agent for the indicated times at 37‡C in the in-
cubation bu¡er (pH 7.4; 120 mM KCl/30 mM NaCl/10 mM
Na2HPO4/0.1 mM EDTA). The total volume was 1.5 ml. The
peptides tested were: FP (b), FP527L/R (U), FP520V/E (8),
FP529F/Y (R), FPCLP1 (F) and FPCLP2 (7). The peptides
were each added to the incubation mixture from a DMSO
(100%) stock solution, yielding a 40 WM peptide concentration
and 2.6% DMSO. DMSO (2.6%) alone has no e¡ect on lipid
mixing [31]. Excitation and emission wavelengths were 560 and
590 nm, respectively. Results are means of duplicate determina-
tions, and are representative of three independent experiments.
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and represents single cells. FP treatment most likely
induces variable aggregations of erythrocytes, with
maximum particle volumes greater than 64 W3. Sin-
gle-site substitutions in the amino acid sequence of
FP diminished red cell aggregation, with LeuCArg
at 527 (FP527L/R) abolishing red cell aggregation
(Fig. 3A), and ValCGlu at 520 (FP520V/E) and
PheCTyr (FP529F/Y) each reducing the %TV for
channels greater than 128 W3 (Fig. 3A,B). Removal
of either 6 residues (FPCLP2) or 7 residues
(FPCLP1) from the N terminus of FP also markedly
depressed aggregation; FPCLP1 showed a maximum
particle volume distribution similar to that of the
DMSO control, while FPCLP2 demonstrated only
minimal aggregation above control (Fig. 3B).
The relative aggregating potency of the various FP
analogs may be quanti¢ed by noting that FP treat-
ment decreases the %TV in the 64 W3 channel, in
parallel with elevations in the %TV of higher chan-
nels (Fig. 3). Since neither FP nor the FP analogs
increased the %TV for channels smaller than 64 W3
(Fig. 3), the peptides do not grossly fragment red
cells. Instead, any decreases in the 64 W3 channel
re£ect reductions in the single cell population caused
by peptide-induced cell aggregation. Consequently,
decreases in the %TV of the 64 W3 channel in Fig.
3 are directly proportional to peptide-induced aggre-
gation. If the %TV in the 64 W3 channel induced by
40 WM FP is arbitrarily rede¢ned as that which rep-
resents 100% aggregation, then the percentage of FP-
induced aggregation for each peptide may then be
calculated from:
% of FPÿ induced aggregation 
100Upeptide %TV643control %TV64=
FP %TV643control %TV64 3
where peptide %TV64, FP %TV64 and control %TV64
are the %(total volumes) in the 64 W3 channel in-
duced by FP analog, FP and control, respectively.
From Eq. 3, the relative aggregating potency of the
peptides decreases in the following order:
FPEFP520V/EsFP529F/YEFPCLP2, FP527L/
R, FPCLP1 (Table 2).
3.4. CD spectroscopic analysis of FP and FP variants
in a membrane-mimic environment
In light of the above cellular activities of FP and
FP variants, it is important to elucidate the respec-
tive peptide conformations in membranes and mem-
brane-mimic environments. CD spectroscopy has
Fig. 3. Coulter counter sizing of erythrocytes treated with the
amino terminal peptide of HIV-1 gp41 (FP) and FP variants.
Erythrocytes were tested for aggregation by incubating 10 Wl of
packed red blood cells, diluted to 0.5 ml in PBS bu¡er, with
the following agents at 37‡C for 30 min: (A) 40 WM FP and
DMSO (2.6%) (8) ; 40 WM FP520V/E and DMSO (2.6%) (O) ;
40 WM FP527L/R and DMSO (2.6%) (R) ; and control (2.6%
DMSO) (b). (B) 40 WM FP and DMSO (2.6%) (8) ; 40 WM
FP529F/Y and DMSO (2.6%) (O) ; 40 WM FPCLP2 and
DMSO (2.6%) (R) ; 40 WM FPCLP1 and DMSO (2.6%) (S) ;
and control (2.6% DMSO) (b). At the end of each incubation,
an aliquot of the mixture was diluted 1/50 000 in isotonic phos-
phate-bu¡ered saline. The number of particles in each size
range (i.e., maximum particle volume W3, x axis) shown was
then determined with a Coulter counter. Percent (total volume)
for the particles in each channel (y axis) is calculated as in Sec-
tion 2. Results are means of duplicate determinations, and are
representative of three independent experiments.
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been previously used to determine the secondary
structures of the N-terminal HIV gp41 peptides in
a variety of lipid or structure-promoting environ-
ments [8,20,22,30,36,37]. Unfortunately, light scatter-
ing artifacts preclude similar measurements for CD
spectra of FP and FP variants with RBC lipids [8].
Here, CD spectroscopy was used to study FP and FP
variants in HFIP:water (7:3, v/v) with 10 mM phos-
phate, pH 7.4, a membrane-mimic solvent which
minimizes light scattering. CD spectra of FP (10
WM) in this solvent indicate considerable K-helix con-
tent with a characteristic double minimum at 208
and 220 nm (Fig. 4); quantitatively similar CD spec-
tra (not shown) were obtained for the FP variants
FP520V/E, FP527L/R and FP529F/Y when sus-
pended at 10 WM in the HFIP solution. The corre-
sponding spectra of FPCLP1 and FPCLP2 share this
double minimum, but show less absorption and are
signi¢cantly shallower (Fig. 4). Computer analysis of
the spectra, using unrestrained least squares ¢t algo-
rithm and polylysine reference data [50], demon-
strated that FP, FP520V/E, FP527L/R and
FP529F/Y exhibit approx. 55% K-helix, approx.
45% random structure with no evidence for L-
strands. For the 23-amino acid sequence FP and
FP variants, these results suggest that approx. 13
residues assume an K-helical conformation. None of
the single-site substitutions apparently perturbs the
overall peptide conformation in this structure-pro-
moting solvent. Similar analyses of the CD spectra
of FPCLP1 and FPCLP2 indicated approx. 45% K-
helix, approx. 55% random structure with no L-
strands. For the 16-residue FPCLP1 and 17-residue
FPCLP2, the CD ¢ndings suggest approx. 7^8 resi-
dues are K-helical. Since deletion of the N-terminal
6^7 residues in the truncated FP peptides (i.e.,
FPCLP1 and FPCLP2) reduces K-helical amino acids
by 5^6 over that in wild-type FP, the simplest inter-
pretation of these CD results is that the K-helical
amino acids encompass the N-terminal residues
519^531, for FP suspended in the HFIP solvent.Fig. 4. CD spectra of the N-terminal peptide of HIV-1 gp41
(FP; solid line) and the truncated FP variants FPCLP1 (dotted
line) and FPCLP2 (dashed line) in the structure-promoting sol-
vent system, hexa£uoroisopropanol:water (7:3, v/v) with 10 mM
phosphate, pH 7.4. Peptide concentrations were 10 WM, the
temperature was 25‡C and the optical path was 5 mm. Spectra
represent the average of eight scans.
Fig. 5. ‘Schi¡er-Edmundson’ wheel diagrams of the amino-ter-
minal peptide of HIV-1 gp41 (FP) and FP variants [51]. The
peptide sequences are indicated by one-letter codes, with amino
acid numbering for the wild-type FP from the HIV LAV1a iso-
late [1]. For the FP520V/E analog, the valine (V) at residue 520
in native FP is replaced by anionic glutamate (E3). For the
FP527L/R analog, the leucine (L) at residue 527 in native FP is
replaced by cationic arginine (R). For the FP529F/Y analog,
the phenylalanine (F) at residue 529 in native FP is replaced by
tyrosine (Y). Amino acid residues participating in the K-helix
are connected to the barrel projection, while non-participating
residues are unattached. These amino acid assignments are
from CD spectral results for FP and FP variants suspended at
10 WM concentration in hexa£uoroisopropanol:water (7:3, v/v)
with 10 mM phosphate, pH 7.4, at 25‡C (see Fig. 4 and text).
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The K-helical structures determined for FP and the
FP variants in the HFIP solvent system may be vis-
ualized with Schi¡er-Edmundson analyses [51]. Fig. 5
is a Schi¡er-Edmundson wheel diagram for FP,
which shows segregation of a glycine ‘stripe’ from
non-polar residues in two distinct hemifaces, charac-
teristic of an amphipathic sequence capable of trans-
membrane insertion. The hydrophobic residues (e.g.,
phenylalanine, isoleucine and leucine) principally lie
to the left of the wheel, while the glycine ‘stripe’
residues primarily lie to the right. Schi¡er-Edmund-
son wheel diagrams for FP520V/E, FP527L/R and
FP529F/Y (Fig. 5) indicate that the amino acid sub-
stitutions for these three FP variants will each par-
ticipate in the K-helix. FP520V/E and FP527L/R in-
sert their respective charged residues into the glycine
‘stripe’ hemiface, while the relatively polar tyrosine
replaces the hydrophobic phenylalanine in the non-
polar hemiface of FP529F/Y. For the truncated pep-
tides FPCLP1 and FPCLP2 in the HFIP solvent, the
residues 525^531 and 526^531 each form respective
K-helices (FPCLP1 and FPCLP2 wheel diagrams not
shown).
3.5. FTIR spectroscopic analysis of FP and FP
variants in model liposomes
It is also important to assess the secondary con-
formations of FP and FP variants in environments
that simulate membranes more closely than HFIP
solutions, such as LUV of POPC:POPG (1:1) in
PBS. Since the zwitterionic POPC and the anionic
POPG are comparable to lipids normally found in
surface membranes, this mixture should more accu-
rately mimic the lipid bilayer. Unfortunately, CD
Fig. 6. FTIR spectra of FP and FP variants in POPC:POPG
liposomes at lipid/peptide (L/P) ratios of 75 (A) and 10 (B). FP
and the FP variants FP520V/E, FP529F/Y, FPCLP1, FPCLP2
and FP527L/R (see Table 1 for amino acid sequences) in a
stock solution of HFIP:water (7:3, v/v) with 10 mM phosphate,
pH 7.4, were added to LUV of POPC:POPG (1:1) lipids in
PBS; FTIR spectra were recorded on peptide:lipid samples
chromatographed with a Sephadex G-50 column to remove
non-liposome associated peptide. The arrows at 1658 cm31 in
A and B indicate the K-helix component, while the arrow at
1629 cm31 in B denotes the L-sheet component.
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spectra of FP and FP variants added to LUV of
POPC:POPG (1:1) in PBS indicated substantial
spectral noise due to light scattering (spectra not
shown), which rendered equivocal measurements of
secondary structure (see also [37]). Because of these
experimental artifacts, FTIR spectra were next re-
corded with FP added to large unilamellar lipid
vesicles of POPC:POPG (1:1) in PBS. To evaluate
the secondary conformation of peptides bound only
to POPC:POPG (1:1), FTIR spectra were measured
on peptide:lipid samples passed through a Sephadex
G-50 column to remove non-liposome associated
peptide. For FP added to POPC:POPG (1:1) lipo-
somes at a low initial ratio of peptide/lipid (P/L) of 1/
75, Fig. 6A shows the FTIR spectrum of the amide I
band, indicating a dominant helical component cen-
tered at 1658 cm31. Subsequent curve ¢tting of the
FP spectrum using the criteria of Susi and Byler [52]
con¢rmed a high proportion of K-helix (1662^1645
cm31), with much smaller contributions due to L-
sheet (1637^1613 cm31 and 1689^1682 cm31), L-
turns (1682^1662 cm31) and disordered (random)
structure (1645^1637 cm31) (see Table 3). At a higher
initial loading (P/L = 1/10), however, the FTIR spec-
trum of FP (Fig. 6B) showed an additional major
band near 1629 cm31 and a relative decrease in the
1658 cm31 band, indicative of predominant L-sheet
besides disordered, K-helical and L-turn conforma-
tions (Table 3). For N-terminal gp41 peptides with
either lipid detergents or model liposomes, FTIR
studies have previously reported that the principal
secondary conformation shifts from K-helix at low
loading to L-sheet at high loading [8,20,29].
FTIR spectra were also recorded with FP variants
(Table 1) added to POPC:POPG (1:1) liposomes. At
low initial P/L ratios of 1/75 for the FP variants, Fig.
6A demonstrates a broad spectral band at approx.
1658 cm31, similar to that seen with the wild-type,
N-terminal HIV-1 gp41 peptide (FP). Spectral decon-
volution veri¢ed the presence of substantial K-helix
structure for each FP variant, although at somewhat
lower levels than that noted for FP; signi¢cant dis-
ordered, K-helical and L-turn conformations were
also observed for the FP variants (Table 3). The
FP variants FP520V/E, FP529F/Y, FPCLP1 and
FPCLP2 each exhibited a conformational shift
from high K-helix at low peptide loading (P/L = 1/
75) to high L-sheet at high loading (P/L = 1/10), anal-
ogous to that noted for native FP (Fig. 6B; Table 3).
Of particular interest is the ¢nding that the FP527L/
R variant maintains high proportions of K-helical
structure and low levels of L-structures, independent
of the peptide concentration (Fig. 6A,B; Table 3).
The association of FP and FP variants with
POPC:POPG was quanti¢ed by recording FTIR
spectra, before (not shown) and after chromato-
graphing peptide:lipid mixtures. For POPC:POPG
incubated with FP at initial calculated peptide/lipid
(P/L) ratios of 1/75 or 1/10, the (Samide)/(SXCOlipid)
for unchromatographed and chromatographed sam-
ples were similar, indicating quantitative FP uptake
(see Section 2). Measurement of these (Samide)/
(SXCOlipid) ratios for FP520V/E, FP529F/Y,
FPCLP1 and FPCLP2 at initial P/L of 1/75 or 1/10
also showed high peptide binding to lipids, with
greater than 75% peptide uptake; contrarily, the
chromatographed ratio for FP527L/R was much
lower for either P/L of 1/75 or 1/10, indicating less
than 25% peptide binding to liposomes at either low
or high initial loading.
Table 3
Proportions of secondary structure for FP and FP variants
with POPC:POPG (1:1) LUV liposomes, as estimated from
FTIR spectra
Peptideb % conformation for peptide with POPC:POPG
liposomesa
P/Lc K-Helix L-Sheet L-Turn Disordered
FP 1/75 60 2 27 11
1/10 17 40 13 29
FP520V/E 1/75 37 24 19 20
1/10 31 55 5 10
FP529F/Y 1/75 41 21 23 15
1/10 0 55 18 27
FP527L/R 1/75 39 16 13 32
1/10 61 2 26 11
FPCLP1 1/75 45 20 13 22
1/10 13 58 14 15
FPCLP2 1/75 24 31 15 30
1/10 5 41 32 22
aSee Section 2 for determination of percent conformations.
bPeptides in a stock solution of HFIP:water (7:3, v/v) with
10 mM phosphate, pH 7.4, were added to LUV of POPC:
POPG (1 mole:1 mole) lipids in PBS; FTIR spectra were re-
corded on peptide:lipid samples chromatographed with a Seph-
adex G-50 column to remove non-liposome associated peptide.
cP/L is the initial peptide to lipid ratio before chromatography
of peptide-lipid mixtures.
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3.6. Hydrophobic moment plot analysis of membrane
interactions with FP and FP variants
The interactions of FP and FP variants with mem-
branes may be further studied using hydrophobic
moment plots [38]. Hydrophobic moment plots o¡er
the potential for estimating not only the topograph-
ical association of peptides with membranes, but also
the degree of peptide self-aggregation [8,53,54].
When a window of 11 residues was earlier used to
survey for potential K-helical sequences in wild-type
FP [8,53], segments ranging from residues 519^529 to
526^536 had coordinates in the transmembrane sec-
tor. Accordingly, these theoretical calculations pre-
dicted a deep penetration of the N-terminal HIV-1
gp41 peptide into the membrane bilayer. In the
present study with peptides suspended in the mem-
brane-mimic HFIP solvent, we ¢nd that FP and the
polar amino acid substituted variants form K-helices
for the 13-residue sequence 519^531, while the trun-
cated peptides FPCLP1 and FPCLP2 adopt respec-
tive K-helices for the 6-residue sequence 526^531 and
the 7-residue sequence 525^531 (Figs. 4 and 5). It
should also be noted that, at low peptide loading
(P/L = 1/75) for FP and FP variants with POPC:
POPG liposomes, the dominant conformation was
K-helical (Fig. 6A; Table 3). If it is assumed that
the K-helical residues are similar in HFIP solution
and POPC:POPG at low peptide loading, then hy-
drophobic moment plots may indicate how the re-
spective K-helical segments interact with membrane
bilayers. For K-helical sequences, Fig. 7 predicts that
each peptide will bind to membranes, in agreement
with our FTIR results with POPC:POPG at a low P/
L of 1/75 (Fig. 6A); however, the reduced lipid af-
¢nity of FP527L/R noted above may be due to the
LeuCArg substitution forcing the peptide close to
the globular-transmembrane multimeric interface
(Fig. 7). The polar amino acid substitutions shifted
the coordinates for the FP variants into the trans-
membrane-multimeric zone in Fig. 7, predicting that
FP527L/R, FP520V/E and FP529F/Y when mem-
brane-bound will be more aggregated within the lipid
bilayer than wild-type FP. Fig. 7 also predicts that
FP527L/R and FP520V/E will each reside closer to
the polar lipid headgroup, as the respective polar
substitutions (LeuCArg for FP527L/R and
ValCGlu for FP520V/E) reduced entry into the hy-
drophobic interior. The truncated peptides FPCLP1
and FPCLP2 will similarly tend to lie on the mem-
brane surface (Fig. 7).
Hydrophobic moment plots may also be used to
evaluate the membrane interactions of FP and FP
variants at high loading. As the P/L ratio is increased
from 1/75 to 1/10, FTIR spectral analysis indicates
that the predominant conformation was converted
from K-helix to L-sheet for FP and the FP variants
FP520V/E, FP529F/Y, FPCLP1 and FPCLP2. If it is
assumed as a ¢rst approximation that those amino
acid residues participating in K-helix at low P/L as-
sume L-sheet conformations at high P/L, then hydro-
phobic moment plots may be used to study mem-
brane lipid-peptide interactions at high loading.
Using a 13-residue window for the FP sequence
519^531, Fig. 7 predicts a deep penetration of the
potential L-sheet segment into the membrane interi-
or, but that FP prefers to exist as a monomer. The
corresponding L-sheet sequences for FP520V/E and
Fig. 7. Hydrophobic moment plot for putative K-helical (closed
symbols) and L-sheet (open symbols) sequences of the amino
terminal peptide of HIV-1 gp41 (FP) and FP variants, using
the computer algorithm of Eisenberg et al. [38]. Hydrophobicity
and hydrophobic moments were calculated for: the 13-residue
sequence (519^531) of FP (K-helix (D) ; L-sheet (C)), FP527L/R
(b, a), FP520V/E (8, 7) and FP529F/Y (S, P) ; the 6-resi-
due sequence (526^531) of FPCLP1 (R, O) ; and the 7-residue
sequence (525^531) of FPCLP2 (F, E). The K-helix and L-sheet
values for FP527L/R are nearly identical. The ¢gure is subdi-
vided into the following membrane regions where the peptide
segments are predicted to reside: (i) surface; (ii) Mul, trans-
membrane multimeric (peptide aggregate); and (iii) Mon, trans-
membrane monomeric [38]. The globular region denotes peptide
segments of low hydrophobic moment and hydrophobicity that
are less likely to be membrane associated.
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FP529F/Y also indicate deep insertion into the mem-
brane interior, with equal propensities for mono-
meric/multimeric states (Fig. 7). Unlike the surface
membrane location estimated for the K-helical se-
quences of FPCLP1 or FLPCLP2 (Fig. 7), the L-
sheet conformations for these sequences are pre-
dicted to insert into the membrane bilayer as mono-
mers (Fig. 7). Of particular interest is the FTIR ¢nd-
ing that the FP527L/R variant retains its high K-
helical proportions, regardless of the P/L ratio (Table
3). Accordingly, FP527L/R is predicted to lie close to
the globular-transmembrane multimeric interface, as-
suming an K-helical conformation for residues 519^
531 at both low and high peptide loading (Fig. 7).
4. Discussion
Most models for HIV infection of CD4 cells pos-
tulate an important role for the N-terminal domain
of the envelope glycoprotein gp41 [3,6,7,14,55,56].
HIV entry into cells is a two-step process [6], in
which the virus binds to cell receptors and then pro-
motes fusion between the lipid bilayers of the viral
envelope [9,10] and cell surface. The targeting occurs
through viral gp120 interacting with host-cell surface
CD4 glycoprotein and one of several coreceptors of
the chemokine family [57^59]. The interaction of
gp120 with cell receptors may expose cryptic gp41
sites [7,55] such as an activated N-terminal gp41 pep-
tide, which may in turn attack the host-cell surface
[60]. Recent X-ray di¡raction studies [32^35] were
interpreted as indicating that gp41 has a multimeric
protein core that presents the N-terminal domain as
a trimer, similarly to the low-pH induced conforma-
tion of in£uenza virus HA2 [61]. This suggests that
gp41 shares aspects of the low-pH induced ‘spring-
loaded’ mechanism for HA2, in which the N-terminal
fusion peptide undergoes a major translocation
[61,62]. Prior structural studies [8,20,27,37] indicated
that synthetic N-terminal gp41 peptide (FP) pene-
trates deeply into membranes. The envelope gp41,
along with possible contributions from gp120 and
cell receptors, could act as a ‘bridge’, linking the
target cell surface bilayer (through the N terminus
of gp41) with the HIV envelope bilayer (through
the embedded transmembrane sequences) [9].
Besides simply tethering the HIV envelope to the
host cell, the gp41 N terminus may participate more
directly in viral-induced fusion. The synthetic N-ter-
minal gp41 peptide (FP; 23 residues) lyses human
red cells (Fig. 1) [28,31,39,49], similarly to that ob-
served for N-terminal gp41 peptides with model lip-
osomes [20^26]. Furthermore, the red cell ghost lipid
mixing (Fig. 2) [31] induced by FP is characteristic of
a classical fusogen, and is comparable to that re-
ported for N-terminal gp41 peptides and model lip-
osomes [20,22^27,29,30]. Such lipid transfers would
be required for the merger between the viral envelope
and the host-cell plasma membrane. It should be
noted that the lipid mixing seen with synthetic N-
terminal gp41 peptides is analogous to that observed
with intact HIV and either CD4 lymphocytes [63]
or red cell membranes and model liposomes [64].
Earlier ¢ndings indicating the participation of
gp120 and gp41 regions outside the N terminus in
HIV-cell fusion [14,65^67] prompted us to reassess
whether synthetic gp41 peptides are a relevant model
for the properties of the N-terminal gp41 domain in
the whole virus. Since sequence modi¢cations in the
N-terminal domain reduced HIV infectivity and syn-
cytia formation in earlier site-directed mutagenesis
experiments [12^15,17], it would be important to
learn whether these alterations similarly blunt pep-
tide-induced red cell lysis and fusion. Accordingly,
FP analogs were synthesized, in which LeuCArg
at residue 527 (FP527L/R) and ValCGlu at 520
(FP520V/E) (see Table 1). FP527L/R and FP520V/
E were chosen because an earlier mutagenic study,
using CD4 HeLa cells transfected with HIV env
glycoprotein expression vectors, indicated that these
replacements strongly inhibited syncytia formation
[12] (Table 2). Another FP analog with PheCTyr
at residue 529 (FP529F/Y; see Table 1) was pre-
pared, because this substitution blocked mutant vi-
rus-induced syncytia of SupT1 target cells [14] (Table
2). Last, a FP analog lacking residues 519^525
(FPCLP1; Table 1) was synthesized, since transfec-
tion of CD4 HeLa cells with this deletion mutant
eliminated syncytia formation [17] (Table 2).
The red cell membrane perturbations achieved by
the above panel of FP analogs were much reduced
when compared to those of the wild-type FP. For
example, the hemolysis induced by FP527L/R,
FP520V/E, FP529F/Y or FPCLP1 was sharply di-
minished (Fig. 1), and correlated well with the de-
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creased fusogenicity of the corresponding mutant
glycoproteins (Table 2). The FP analogs also exhib-
ited substantially less fusion activity than that of FP,
as indicated by lowered lipid mixing and red cell
aggregation. Although our results show that pep-
tide-induced hemolysis, lipid mixing or aggregation
may each be used to simulate the activity of the gp41
N terminus in HIV fusion processes, Table 2 suggests
that FP-induced hemolysis provides the most accu-
rate model. These results broadly agree with earlier
studies contrasting the lysis/fusion induced by the N-
terminal gp41 peptides with the fusion activity of the
parent glycoprotein. For example, FP causes leakage
and lipid mixing of resealed RBC ghosts, as well as
aggregation of red cells, while FP527L/R was inac-
tive [31]. Similar to our ¢ndings with FP520V/E
(Figs. 1 and 2), Pereira et al. [25,27] reported that
the ValCGlu substitution at residue 520 (HIValaÿE2)
depresses the lytic and lipid-mixing activities of the
FP peptide (residues 519^541; HXB-2 strain) with
model liposomes. Also in agreement are the results
from Kliger et al. [30], who showed that the
ValCGlu replacement at residue 520 abolished the
lipid-mixing activity of the 33-residue N-terminal
gp41 peptide (residues 519^551; LAV1a strain).
Last, the leakage induced from model liposomes by
the deletion N-terminal gp41 analogs SP-3 and SP-4
(i.e., removal of 3 (residues 520^522) or 4 amino
acids (residues 520^523), respectively) was dramati-
cally reduced over that of the wild-type peptide (16
residues; 519^536) [29], in parallel with the depressed
syncytia-forming activities of the corresponding mu-
tated gp41 [17]. The above results not only indicate
that the highly conserved N-terminal gp41 region
participates in key HIV fusion processes, but also
that addition of synthetic FP (and FP analogs) to
red cells or model liposomes is a useful model for
investigating these activities. Additional support for
these conclusions is the earlier ¢nding that anti-HIV
agents which block the membrane actions of the N-
terminal gp41 peptide also reduce viral-mediated fu-
sion [39]. The ‘capture’ of lytic and fusogenic proper-
ties of HIV-1 gp41 by the N-terminal peptide may
re£ect a general phenomenon for lipid-enveloped vi-
ruses, as an analogous fusion peptide has been re-
ported for the in£uenza virus [18,68^70].
It is important to identify those cell components
which interact with the N-terminal HIV-1 gp41 pep-
tide. The present FTIR studies show that FP binds
to model lipids, suggesting that the surface lipid is
one such target. Earlier physical investigations con-
¢rm that N-terminal gp41 peptides associate with
liposomes [8,20,23^25,27,29,30]; functional experi-
ments indicate that these peptides also promote lysis
and fusion of liposomes [20,22,23,25^27,29,30]. Giv-
en that FP binds to liposomes made from red blood
cell extracts [8], the N-terminal gp41 peptide may
produce red cell lysis (Fig. 1), lipid mixing (Fig. 2)
and aggregation (Fig. 3A,B) by interacting with the
lipid bilayer. Such peptide-induced perturbations are
not simply due to non-speci¢c, ‘detergent-like’ ef-
fects. FP has been shown to aggregate red cells in
electron microscopy studies, but does not severely
disrupt membranes as would be expected if the pep-
tide simply acted as a chaotropic agent [31]. More-
over, the relatively minor modi¢cations in our FP
analogs (Table 1) substantially decreased lysis and
fusion, indicating that the N-terminal gp41 peptide
requires a highly conserved structure to mediate in
vivo lipid perturbations. The results on erythrocytes
and lipids presented here suggest that FP-induced
cytolysis of CD4 lymphocytes [28] is similarly due
to peptide binding to cell-surface membrane lipid,
particularly since the red cell bilayer lipid composi-
tion, asymmetry and cholesterol/phospholipid ratio
approximate those in lymphocytes [9]. It is tempting
to further speculate that the gp41 N terminus in in-
tact HIV will induce analogous lytic and fusogenic
activities with CD4 lymphocytes. The related N-ter-
minal peptide of in£uenza HA2 has also been pro-
posed to induce fusion through interactions with
membrane lipids [3,68^71].
The CD spectroscopic studies on native and trun-
cated N-terminal gp41 peptides in the membrane-
mimic HFIP solution (Fig. 4) permit the assignment
of the K-helical domain within the FP sequence (Fig.
5). This technique has previously been used to iden-
tify discrete conformations within the N-terminal do-
main SP-B (SP-B1ÿ25 ; 25 residues) for peptides sus-
pended in structure-promoting environments [42].
High levels of K-helix were found here for FP in
HFIP solution, similarly to that reported earlier for
N-terminal HIV gp41 peptides in such membrane
mimetics as TFE or SDS [8,22,30,36,37]. Quantita-
tive comparisons between the CD spectra of FP and
clipped forms of FP in HFIP solution indicated an
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K-helical conformation for residues Ala-519 to Gly-
531 (Fig. 5). It is worthwhile to compare these results
with those from residue-speci¢c physical techniques.
Chang et al. [36,37] observed with 2D-NMR spectro-
scopy that FP in structure-promoting 50% TFE as-
sumed an K-helical conformation for residues Ile-522
to Ala-533, while the corresponding K-helix is
slightly more extensive for FP bound to SDS deter-
gent micelles, spanning residues Val-520 to Gly-534.
For FP suspended in HFIP solvent, mass spectro-
metric analysis of hydrogen/deuterium exchange sim-
ilarly indicated K-helix for residues Gly-523 to Ala-
533 [72]. Molecular modeling of HIV-1 FP (not
shown) indicated that the carboxyl terminus of the
helix was probably a glycine-based cap at Ala-533
known as the KL motif [73], characterized by Gly-
534 assuming a left-handed conformation and a sin-
gle hydrogen bond between the sN-H at Gly-534
and sC = O at Leu-530.
The N-terminal HIV-1 gp41 peptide (FP) assumes
K-helical conformations not only in HFIP solution
and SDS, but also in model liposomes. With a low
N-terminal gp41 peptide/lipid of 1/75 that is non-
lytic and non-fusogenic (Figs. 1^3) [20,23^
25,27,29,30], FTIR spectra indicate that FP in
POPC:POPG has high levels of K-helix (Fig. 6A;
Table 3). These results may be considered in light
of a review [74] questioning whether viral fusion pep-
tides form helices in membranes. Gallaher et al. [74]
raised concerns about the frequency of amino acids
in FP (e.g., Gly, Ser) which are helix breaking in
soluble proteins. Nevertheless, the present ¢ndings
agree with earlier CD and FTIR studies showing
that N-terminal gp41 peptides may form substantial
K-helix in model liposomes and lipid extracts from
membranes [8,20,23^25,27,29,37]. The experimental
results with FP may be reconciled with the criticisms
of Gallaher et al. [74] as follows. Although Gly, Val
and Ile are ‘helix destabilizers’ in soluble proteins
[74^76], Li and Deber [75,76] reported that these res-
idues are instead K-helix promoters when incorpo-
rated into membranes. The elevated K-helix for FP
in liposomes argues that the Gly, Val and Ile residues
of FP are drawn into the hydrophobic interior of the
lipid bilayer, where they become K-helical. Indeed,
deep penetration of N-terminal gp41 peptides into
membrane bilayers has been predicted from hydro-
phobic moment plots (Fig. 7) [8,53] and veri¢ed with
a range of physical measurements [8,20,27,37]. The
residue-speci¢c structure model proposed for FP in
the membrane-mimic HFIP solution (Fig. 5) may
also account for the K-helical component in FTIR
spectra of FP with POPC:POPG at low peptide/lipid
(Fig. 6A; Table 3); speci¢cally, FP intercalates
deeply into the lipid bilayer as an K-helix (Ala-519
to Ala-533). Such FP-lipid interactions may assist in
the docking of HIV-1 to target cells, in which FP
extends from viral gp41 to ‘hook’ the HIV-1 enve-
lope to the lymphocyte surface membrane.
The present FTIR experiments also con¢rm that
HIV-1 FP may assume conformations other than K-
helix in lipid environments at high peptide loading.
Raising the peptide/lipid from 1/75 to 1/10 converted
the principal component from K-helix to L-sheet, for
FP incubated with POPC:POPG liposomes (Fig.
6A,B; Table 3). For N-terminal gp41 peptides incu-
bated with either lipid detergents or model lipo-
somes, previous FTIR studies have similarly shown
a shift from K-helix at low loading to L-sheet at high
loading [8,20,29]. Structural investigations of N-ter-
minal gp41 peptides at high loading are of particular
interest, since P/L ratios sV1/25 with model lip-
osomes are lytic and fusogenic [20,23^25,27,29,30].
Earlier work with N-terminal gp41 peptides has in-
dicated possible roles for the deep insertion of pep-
tide into lipid bilayers [8,20,27,37], oblique intercala-
tion of helical peptide into membrane lipids [23,29],
membrane aggregation of peptides [8,30], or the for-
mation of membrane-associated peptide in L-confor-
mations [8,24,25]. Despite these extensive spectro-
scopic studies with wild-type N-terminal gp41
peptides, there is no generally accepted model for
how FP interactions with membranes produce lysis
and fusion.
Our physical studies with FP and FP variants al-
low us to more rigorously test several of the pro-
posed models for how native HIV-1 FP mediates
lysis and fusion. As discussed above, one explanation
for FP-induced perturbations is the transformation
of membrane-associated K-helix to L-sheet [8,24,25].
Consistent with this model are our results indicating
that the functionally inactive FP527L/R (Figs. 1^3)
does not form substantial lipid-bound L-sheet at ei-
ther low or high peptide loading of POPC:POPG
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(Fig. 6A,B; Table 3). Nevertheless, further experi-
ments with the other FP variants do not support a
functional role for membrane-associated L-sheet. Ad-
dition of FP520V/E, FP529F/Y or FPCLP1 to
POPC:POPG each indicated high levels of lipid-
bound K-helix at a low P/L of 1/75; at a high P/L
of 1/10, each FP variant exhibited substantial con-
versions of lipid-associated K-helix to L-sheet (Fig.
6A,B; Table 3). The shift of lipid-bound K-helix to
L-sheet noted for wild-type FP at high loading is
similar to that observed with FP variants (Fig.
6A,B; Table 3). Since FP520V/E, FP529F/Y or
FPCLP1 each show sharply reduced lysis (Fig. 1)
and fusion (Figs. 2 and 3) at high peptide loading,
the high lipid-associated L-sheet observed for each
FP variant does not promote lysis or fusion. It is
reasonable to infer that the global conversion of K-
helix to L-sheet noted for wild-type FP (Fig. 6A,B;
Table 3) is coincidental with, rather than integral to,
peptide-induced lysis and fusion. Two previous FTIR
investigations using analogs (i.e., HIValaÿE2, SP-3
and SP-4) of the N-terminal HIV-1 gp41 peptide
[27,29] similarly con¢rm that global shifts of K-helix
to L-sheet do not facilitate lysis and fusion.
Together with results from earlier studies
[8,20,27,37], the structural and functional experi-
ments presented here indicate an important function-
al role for deep insertion of the N-terminal HIV-1
gp41 peptide into the membrane bilayer. The de-
pressed fusion and cytolysis reported for FP527L/R
may be partly due to the reduced peptide binding to
bilayer lipid that was determined from FTIR spectra.
Substitution of the positively charged Arg for hydro-
phobic Leu-527 creates a more soluble, ‘globular’
peptide in hydrophobic moment plots (Fig. 7). For
the low levels of FP527L/R that still bind to lipid
(Fig. 6A,B), Fig. 7 predicts that the Arg-substituted
peptide will be more restricted to the polar head-
group region of the membrane surface. The net e¡ect
of the Leu-527CArg replacement is to reduce the
deep insertion of FP527L/R into the bilayer, and
this may be responsible for depressed activities. The
reduced membrane perturbations noted for the
FP520V/E variant (Figs. 1^3) may also be due to
the inability of this peptide to bury deeply into the
bilayer interior. Although both the present FTIR
uptake studies (Fig. 6A,B) and earlier investigations
[25,27,30] show high liposome uptake of N-terminal
gp41 variants with Val-520CGlu, hydrophobic mo-
ment analysis (Fig. 7) predicts that the negatively
charged Glu replacement will tend to limit the K-
helical FP variant to the polar headgroup region.
Pereira et al. [27] experimentally con¢rmed a sur-
face-membrane location for a Val-520CGlu substi-
tuted N-terminal gp41 peptide, using extrinsic £uo-
rescent probes that monitor the surface and interior
of lipid bilayers. Last, the lowered lytic and fusion
activities of truncated FPCLP1 and FPCLP2 (Figs.
1^3) may be explained by the Fig. 7 prediction that
these are ‘surface-seeking’ peptides when K-helical,
due to the lack of the N-terminal AVGIGA se-
quence. With similarly truncated N-terminal gp41
peptides (i.e., SP-3 and SP-4), Martin et al. [29] re-
ported K-helical orientations nearly parallel to the
lipid bilayer plane. These N-terminal deletions may
generate FP variants with amphipathic K-helices ly-
ing £at on the membrane surface.
Insertion of the N-terminal HIV-1 gp41 peptide
into membrane lipid may represent only a critical,
initial step in multi-step lytic or fusion processes. A
related phenomenon may be the formation of FP
aggregates in lipid bilayers at high peptide loading,
as indicated by earlier ESR spectroscopy of mem-
branes incubated with spin-labeled FP [8]. Hydro-
phobic moment analysis predicts that the amino
acid substitutions found in FP520V/E, FP527L/R
and FP529F/Y may promote the formation of mem-
brane peptide aggregates, whether the N-terminal re-
gion is K-helical or L-sheet (Fig. 7). Membrane-asso-
ciated FP aggregates have been earlier proposed to
act in HIV infection as ‘fusion pores’, which not only
destabilize the lipid bilayer but also trigger fusion
between the viral envelope and cell surface
[3,6,13,15]. The amino acid substitutions in the N-
terminal gp41 domain may here create defective
membrane pores, which on the one hand reduce pep-
tide-induced hemolysis and fusion and on the other
block gp41-mediated syncytia [12,13,15]. The above
models for the membrane activities of the gp41 N
terminus should be further tested with physical stud-
ies of synthetic FP and FP analogs (e.g., 13C-en-
hanced FTIR and ESR spectroscopy) that map the
conformation, orientation and local environment of
individual amino acids [8,42,77].
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